Dry Eye Pharmacologic & Device Therapy

Overview

Dry eye turns into a self-sustaining inflammatory process once the tear film's hyperosmolarity-driven vicious cycle takes hold, so most therapy beyond over-the-counter tears aims at breaking that cycle rather than just adding fluid. The agents below fall into a few functional groups: immunomodulators that quiet T-cell-driven surface inflammation, agents that replace a deficient tear component directly, secretagogues that push the eye's own glands to secrete more, and mechanical or biologic options for disease too severe for pharmacology alone.

Anti-Inflammatory Topical Agents

Cyclosporine A (Restasis, Cequa)

Restasis is a 0.05% emulsion of topical cyclosporine A, an immunomodulator that inhibits calcineurin. Blocking calcineurin prevents dephosphorylation of NFAT, which lowers T-lymphocyte activation and cuts production of the inflammatory cytokines (IL-6 and IL-8 among them) implicated in dry eye's surface inflammation. Because the drug targets chronic T-cell-mediated disease rather than providing immediate relief, full benefit typically takes 3 to 6 months of continuous use. Patients need to be told this up front: early discontinuation for lack of quick results is a common reason cyclosporine appears to fail.

A short course of topical corticosteroids is often added at the start of cyclosporine therapy as a bridge, covering the induction period with fast symptomatic relief before cyclosporine takes over. The steroid is then tapered off, avoiding the cataract and glaucoma risk that comes with chronic topical steroid use.

Lifitegrast (Xiidra)

Lifitegrast is a small-molecule integrin antagonist. It blocks the interaction between lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1), inhibiting T-cell adhesion, migration, and activation at the ocular surface. The endpoint is the same T-cell suppression cyclosporine achieves, reached by blocking the adhesion step instead of intracellular calcineurin signaling.

Tear Film Replacement & Stabilizing Agents

Perfluorohexyloctane (Miebo)

Perfluorohexyloctane is a semifluorinated alkane that spreads as a monolayer over the tear film's surface, slowing evaporation. Rather than modulating inflammation, it targets the lipid layer deficiency of evaporative dry eye directly, functioning as a synthetic stand-in for the deficient meibomian lipid layer.

Diquafosol Tetrasodium

Diquafosol is a P2Y2 purinergic receptor agonist, used in some countries though not FDA-approved in the United States. It stimulates conjunctival goblet cells and non-lacrimal gland tissue to secrete both mucin and fluid at once. Where perfluorohexyloctane replaces one tear component from outside, diquafosol boosts the eye's own secretion of several.

Secretagogues

Secretagogues take a third approach. Instead of replacing tear components or quieting inflammation, they push the eye's own lacrimal apparatus to make more.

Varenicline Nasal Spray (Tyrvaya)

Tyrvaya's active ingredient is varenicline, delivered as a nasal spray. It activates nicotinic acetylcholine receptors on trigeminal nerve endings in the nasal mucosa, triggering a neural reflex that stimulates lacrimal gland tear secretion. This is a pharmacologic route into the same trigeminal-parasympathetic reflex arc that Schirmer II testing assesses mechanically.

Intranasal Neurostimulation (TrueTear)

The TrueTear device reaches a related effect through hardware rather than a drug. Microcurrent stimulation delivered to the nasal mucosa activates trigeminal afferents, triggering the same parasympathetic reflex arc to the lacrimal gland and increasing production of all three tear film layers, with no pharmacologic agent involved.

Oral Cholinergic Agonists

In Sjögren syndrome-associated dry eye and dry mouth, oral muscarinic agonists such as pilocarpine or cevimeline stimulate whatever residual functional lacrimal and salivary gland tissue remains. Tear and saliva production both rise systemically, rather than just at the ocular surface.

Biologic & Regenerative Therapies

For severe disease with significant ocular surface damage, biologic and tissue-derived therapies supply growth factors and regenerative signals that no standard drop can.

Autologous Serum Tears

Prepared from a patient's own blood, typically diluted to roughly 20 to 50% serum in preservative-free saline, autologous serum tears contain growth factors (EGF and TGF-beta among them), vitamin A, fibronectin, and immunoglobulins that mimic natural tear composition and support epithelial healing. None of this is present in commercial artificial tears.

Platelet-Rich Plasma Eye Drops

Platelet-rich plasma is centrifuged to concentrate platelets, which upon activation release growth factors, including PDGF, EGF, and TGF-beta, that drive epithelial cell proliferation, migration, and wound healing. The concept is close to autologous serum tears, just with a higher concentration of growth factors.

Amniotic Membrane Transplantation

Cryopreserved amniotic membrane promotes healing in severe ocular surface disease through anti-inflammatory, anti-fibrotic, and anti-angiogenic properties. These are mediated largely by heavy chain-hyaluronic acid/pentraxin 3 (HC-HA/PTX3) complexes in its extracellular matrix, which suppress inflammatory cytokines, inhibit fibroblast transformation into myofibroblasts, and block neovascularization. Together they promote epithelial regeneration in ways no drop-based therapy can match.

Mechanical & Device-Based Options

Punctal Occlusion

Punctal plugs conserve the patient's own tears by blocking drainage through the puncta. Active ocular surface inflammation should be adequately controlled before placement. Occluding the puncta while inflammation is unresolved risks trapping pro-inflammatory cytokines and matrix metalloproteinases on the ocular surface instead of letting them drain away, which can worsen symptoms rather than improve them.

Scleral Contact Lenses

In severe dry eye with ocular surface exposure, rigid gas-permeable scleral lenses vault entirely over the cornea, creating a continuous fluid reservoir of preservative-free saline between the lens and the corneal surface. That reservoir keeps the cornea constantly hydrated and mechanically shields the epithelium from the environment and from eyelid-related shear forces, a mechanism unlike any drop or biologic above.

Oral Therapy & Supplements

Oral Tetracyclines

For MGD-associated dry eye, oral tetracyclines such as doxycycline are commonly prescribed for their anti-inflammatory and lipid-modulating effects. They reduce bacterial lipase production at the lid margin and carry their own anti-inflammatory and matrix metalloproteinase-inhibiting properties, improving meibomian secretion quality independent of any antibacterial action.

Omega-3 Fatty Acid Supplementation

Oral omega-3 fatty acids (EPA/DHA) are commonly recommended to reduce ocular surface inflammation, particularly in MGD. Omega-3s compete with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production away from pro-inflammatory prostaglandins and leukotrienes and toward less inflammatory mediators. Clinical trial evidence on actual efficacy remains mixed.

Safety Considerations

Preservatives matter too. Benzalkonium chloride (BAK), the detergent preservative found in many multi-dose artificial tear formulations, disrupts the tear film lipid layer and can cause corneal epithelial toxicity and apoptosis with chronic exposure. Patients using drops frequently, or with already-severe dry eye, generally do better on preservative-free formulations.

Related Topics

Continue exploring Cornea & External Disease: